Pfizer (PFE) delivered earnings and revenue surprises of +16.81% and +4.26%, respectively, for the quarter ended December ...

“Pfizer appears cheap with a near 7% yield, but capital allocation constraints undermine its investment case. Nearly all of ...

Analysts expect the New York-based company to report quarterly earnings at 57 cents per share, down from 63 cents per share ...

Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend offer upside. Click for this PFE update.

Pharmaceutical giant Pfizer (PFE) released its fourth quarter earnings results that topped Wall Street's expectations on its ...

Analysts expect Pfizer’s revenue to decrease approximately 5% to around $16.95 billion, while adjusted earnings per share are projected to fall 9.5% to 57 cents compared to 63 cents in the same period ...

All eyes are on pharmaceutical giant Pfizer as it prepares to release its fourth-quarter and full-year 2025 financial results on February 3. This report is widely viewed as a critical indicator of the ...

Pfizer beat analysts’ revenue expectations by 0.6% last quarter, reporting revenues of $16.65 billion, down 5.9% year on year. It was a mixed quarter for the company, with a beat of analysts’ EPS ...

A month has gone by since the last earnings report for Pfizer (PFE). Shares have added about 3.9% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...

According to TipRanks.com, Skor is a 5-star analyst with an average return of 23.6% and a 67.9% success rate. Skor covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, ...